AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02147678
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During anesthesia maintenance, all patients will be given remifentanil at the speed of 0.2\~0.4 μg/kg/min.
Trial: NCT02147678
Drug: Anesthesia induction
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For all patients, the induction protocol is midazolam 0.1 mg/kg, sufentanil 0.3 μg/kg, cisatracurium 0.15 mg/kg.
Trial: NCT04247386
Drug: PEG-Mizone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The evening before the colonoscopy:60gPEG-4000 was mixed with 0.6LMizone and 0.4L water.~On the day of the colonoscopy:4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 1.2LMizone and 0.8L water.
Trial: NCT04247386
Drug: PEG-ELS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The evening before the colonoscopy:60gPEG-4000 was mixed with 1L water. On the day of the colonoscopy:4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 2L water.
Trial: NCT01650558
Drug: Standard of Care prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily trimethoprim sulfamethoxazole
Trial: NCT00420212
Drug: BG00012
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00420212
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04142762
Drug: ABI-H2158
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABI-H2158 tablets
Trial: NCT02730481
Drug: Oraxol
RxNorm normalized name: doxycycline hyclate Oral Capsule [Oraxyl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.
Trial: NCT04142762
Drug: Ethinyl Estradiol / Levonorgestrel
RxNorm normalized name: ethinyl estradiol / levonorgestrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethinyl Estradiol / Levonorgestrel tablets
Trial: NCT04142762
Drug: Placebo matching oral contraceptive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching Ethinyl Estradiol / Levonorgestrel tablets
Trial: NCT00526292
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day -6 cyclophosphamide 60mg/kg infused over 1 hour (dose adjusted for body weight) for 2 days
Trial: NCT00946842
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
Trial: NCT00946842
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
Trial: NCT02462889
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injection
Trial: NCT02483611
Drug: Isotonic Solution
RxNorm normalized name: Isotonic solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00976261
Drug: GSK1614235
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose lowering in Type 2 Diabetes Mellitus
Trial: NCT03817931
Drug: Anticholinergic
RxNorm normalized name: Anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet taken once daily.
Trial: NCT03817931
Drug: Beta-3 Agonists, Adrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet taken once daily.
Trial: NCT04169698
Drug: Alendronate 70Mg Tab
RxNorm normalized name: ALENDRONATE 70MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisphosphonates
Trial: NCT03418155
Drug: Treatment of TongBi placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TongBi placebo:0.31g,3times a day, oral, for 4 weeks.
Trial: NCT04077021
Drug: CCW702
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational immunotherapy for prostate cancer
Trial: NCT00151567
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo of tamsulosin once a day until stone elimination or the end of the follow-up (42 days)
Trial: NCT01710904
Drug: Targinact® (oxycodone/naloxone)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01528618
Drug: 5-Fluorouracil and cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The FP regimen consists of 5-Fluorouracil 1,000 mg/m2/day which was administered as a continuous intravenous infusion for 96 hours after completion of the cisplatin on days 1( 80 mg/m2 i.v. infusion for 4 h)
Trial: NCT02130635
Drug: GSK2269557 500 MCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device
Trial: NCT02130635
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose administered using a matching dry powder inhaler device
Trial: NCT02826746
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the same bolus and infusion volumes of normal saline
Trial: NCT02654782
Drug: 5% Human Albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloid given for hemodynamic resuscitation based off of individual patient needs.
Trial: NCT03085394
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative intravenous administration of 10 ml saline
Trial: NCT03206684
Drug: PEG-rhG-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-rhG-CSF single-dose was administered subcutaneously 48h after chemotherapy，weight ≥ 45kg were given 6mg once per chemotherapy cycle, weight \<45kg were given 3mg once per chemotherapy cycle.
Trial: NCT03074331
Drug: SOF/VEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400/100 mg FDC tablet(s) administered orally once daily
Trial: NCT00468052
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 microgram/kilogram as a bolus
Trial: NCT00077493
Drug: BL22 immunotoxin
RxNorm normalized name: hepatitis B immunoglobin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BL22 immunotoxin IV over 30 minutes on days 1, 3, and 5 OR on days 1, 3, 5, 7, 9, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) or unconfirmed CR (CRu) receive 2 additional courses beyond CR or CRu for a maximum of 6 courses.
Trial: NCT00296868
Drug: ascorbic acid (vitamin C) versus placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00656994
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon placebo-matching tablets, orally, once nightly for up to 6 months
Trial: NCT03189589
Drug: GSK2269557 500 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 500 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.
Trial: NCT01132391
Drug: Rectogesic® (glyceryl trinitrate 0.4% ointment)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mg of ointment(1,5 mg of glyceryl trinitrate ) / 12h DURING 6 MONTHS
Trial: NCT03189589
Drug: GSK2269557 750 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 750 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.
Trial: NCT03918967
Drug: CT-G11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet of CT-G11 Experimental Drug
Trial: NCT03918967
Drug: CT-G11 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet of Placebo
Trial: NCT03918967
Drug: CT-G20 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet of Placebo
Trial: NCT02204982
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo (25 mg BID) administered orally in 28-day continuous treatment cycles.
Trial: NCT02740231
Drug: JTA-004 intra-articular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will undergo a single injection of JTA-004 into the knee joint
Trial: NCT01546753
Drug: Walnut Protein Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinded study product dosing begins with a 1-day oral desensitization protocol to walnut for subjects in the active arm. Starting at 0.1 mg protein and increasing to a maximum of 6 mg or until allergic symptoms develop. Subjects continue daily dosing of blinded OIT (walnut) with build-up every 2 weeks to a maximum daily dose of 1500mg at week 34, followed by 4 weeks of daily maintenance dosing. OFC to walnut and second tree nut occurs at week 38 then treatment is unblinded and open-label maintenance dosing occurs.
Trial: NCT02313220
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and Subcutaneous use.
Trial: NCT02513355
Drug: Changchun marina
RxNorm normalized name: Zostera marina whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mg/m2,d1 and d8,q21d×4
Trial: NCT01546753
Drug: Oat Powder (placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinded study product dosing begins with a one-day oral desensitization protocol with placebo (oat) powder. Subjects in the placebo group will undergo the same protocol as those in the active group with placebo OIT dosing. Unblinding to treatment assignment will occur after the 38 week oral food challenge. Placebo subjects will cross-over to active, open-label treatment with walnut powder after the 38 week oral food challenge. beginning with initial escalation day, through build-up and maintenance dosing per the same protocol sequence as noted for active, walnut powder. Subjects will complete an oral food challenge to walnut and the second tree nut at week 38 then will continue on long-term, open-label maintenance dosing until the end of study using same protocol design.
Trial: NCT01546753
Drug: Open-label Walnut Protein Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label treatment phase begins after the 38 week oral food challenge with unblinding of treatment assignment. For those on active treatment, daily maintenance dosing occurs for up to a total of 298 weeks. For those on placebo treatment, cross-over to active, open-label treatment occurs using the same active treatment protocol. Placebo-crossover subjects will complete an oral food challenge to walnut and the second tree nut at week 38 of active therapy then continue on long-term, open-label maintenance dosing until the end of study using same protocol design. All subjects may reach a qualifying IgE to walnut/second tree nut early and will undergo an OFCs on and 4 weeks off OIT. All subjects will have OFCs on and 4 weeks off OIT at week 142 and at week 298, unless both walnut/second tree nut OFCs are passed at previous OFC prompting addition of these foods into the diet.
Trial: NCT02607735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally once daily with food
Trial: NCT01590446
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC injection, Part 1 single dose and Part 2 multiple dose
Trial: NCT01416818
Drug: Xiaoyao Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: herb extracts,were received two times a day for 12 weeks without dose changing.
Trial: NCT01416818
Drug: Bupleurum+Ginkgo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: herb extracts, were received two times a day for 12 weeks without dose changing.
Trial: NCT01416818
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo looked like herb extracts and were also received two times a day for 12 weeks without dose changing.
Trial: NCT01646255
Drug: Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal Patch~Size:~20 cm\^2, 30 cm\^2, 40 cm\^2~Subjects randomized to placebo received matching placebo patches
Trial: NCT01376908
Drug: Kuvan®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kuvan® (sapropterin dihydrochloride) tablets will be administered orally at the dose of 10 mg/kg/day and will be escalated to 20 mg/kg/day if after 4 weeks a subject's Phe tolerance is not increased by at least 20% versus baseline.
Trial: NCT00004172
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00093015
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume and dose frequency changes resembling dosing in the active treatment group
Trial: NCT00742391
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two day treatment
Trial: NCT01744340
Drug: Head and neck
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eribulin mesylate is administered by IV infusion over 2-5 minutes on day 1 and 8 of a 21 day cycle 1.4mg/m2 and Cetuximab 400 mg/m2 cycle 1 week 1, then 250 mg/m2/weekly thereafter~Dose Level 1: 0.7 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 2: 1.0 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 3: 1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle
Trial: NCT01744340
Drug: Colon- Closed as of May 2014
RxNorm normalized name: Bos Taurus Colon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eribulin Mesylate:~1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle
Trial: NCT02178592
Drug: DTG 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTG is available as 50 mg film-coated tablet. DTG may be administered with or without food
Trial: NCT02178592
Drug: EFV 600 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EFV is supplied as film-coated capsule-shaped oral tablet containing 600 mg of EFV and must be administered without food
Trial: NCT01346982
Drug: Silimarine
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: darunavir/ritonavir 600/100 mg + silimarine (150 mg every 8 hours)
Trial: NCT03830086
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Used for regional anesthesia (spinal or combined spinal-epidural anesthesia) for gynecological laparoscopic procedures together with Bupivacaine; and for general anesthesia for gynecological laparoscopic procedures, together with following drugs: Midazolam, Propofol, Rocuronium, Sevoflurane
Trial: NCT03215017
Drug: Medication
RxNorm normalized name: Acne Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication to help control of the bowel movement (One or a combination of Loperamide, Sorbitol, Sterculia gum)
Trial: NCT00392054
Drug: Conventional Antiarrhythmic Drug Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-Arrhythmic Drugs per ACC/AHA 2006 Guidelines for the Management of Patients with AF
Trial: NCT01302236
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg/day for all as initial dose, 100mg/day for the patients that still show hypertension(above 140/90mmHg)after one month 150mg treatment,oral,on 6 months
Trial: NCT02569645
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg rosuvastatin orally once per day with or without food, swallowed whole (not chewed, crushed or divided) starting 2 weeks prior to the initiation of radiation therapy and stopped at 4 weeks after the completion of radiation. Total duration of Rosuvastatin is 11 weeks if 25 fractions of radiotherapy are given, or 12 weeks if 30 fractions of radiotherapy are given.
Trial: NCT01834469
Drug: iv injection of ICG
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An iv injection will be performed for the ovarian cancer patient before the operation.
Trial: NCT02056665
Drug: MINOCYCLINE
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pill Minocycline 50 mg capsule
Trial: NCT02056665
Drug: PLACEBO (for Minocycline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill manufactured to mimic Minocycline 50 mg capsule
Trial: NCT03700294
Drug: ADCT-601
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV)
Trial: NCT00973752
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenously during Induction, CNS, and Consolidation 2 therapy
Trial: NCT00973752
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecally during Induction, CNS, and Continuation Therapy
Trial: NCT00973752
Drug: 6 Mercaptopurine
RxNorm normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally during CNS, Consolidation 2 and Continuation Therapy
Trial: NCT02365272
Drug: Amikacin
RxNorm normalized name: amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amikacin administered in a single dose for critical care patients
Trial: NCT00703781
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterile ophthalmic solution
Trial: NCT04322266
Drug: HCP1701
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe / Rosuvastatin / Amlodipine / Losartan potassium
Trial: NCT04322266
Drug: HCP1306
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe /Rosuvastatin
Trial: NCT04322266
Drug: HGP0904
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine
Trial: NCT04322266
Drug: HGP0608
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan potassium
Trial: NCT02168816
Drug: Intravenous Antibacterial Agent
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individuals in this arm receive an intravenous antibacterial agent. They are not assigned to specific medications. Individuals in this arm will receive an intravenous antibacterial agent as determined by their primary healthcare provider. This therapy is usually one of the following intravenous medications: (i) piperacillin/tazobactam (Zosyn), (ii) cefepime, (iii) metronidazole, (iv) aztreonam, (v) vancomycin, (vi) daptomycin, (vii) linezolid (Zyvox), and/or (viii) meropenem.
Trial: NCT01855334
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01855334
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02168816
Drug: Oral Antibacterial Agent
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individuals in this arm receive an oral antibacterial agent. They are not assigned to specific medications. Individuals in this arm will receive an oral antibacterial agent as determined by their primary healthcare provider. This therapy is usually one of the following oral medications: (i) sulfamethoxazole/trimethoprim (SMX-TMP), (ii) clindamycin (Clindesse), (iii) linezolid (Zyvox), (iv) moxifloxacin (Avelox), (v) ciprofloxacin (Cetraxal), and/or (vi) metronidazole (Flagyl)
Trial: NCT04387448
Drug: GFB-887
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational Medicinal Product (IMP)
Trial: NCT04387448
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching
Trial: NCT03446625
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.
Trial: NCT00546754
Drug: losartan potassium (+) hydrochlorothiazide
RxNorm normalized name: hydrochlorothiazide / losartan potassium Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan potassium 50 mg/12.5 Hydrochlorothiazide (HCTZ) titrated as needed to losartan potassium 100 mg/25 mg Hydrochlorothiazide
Trial: NCT00546754
Drug: Comparator: Valsartan (+) Hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 80 mg/ Hydrochlorothiazide 12.5 mg/day titrated as needed to valsartan 160 mg/25 mg Hydrochlorothiazide
Trial: NCT03040141
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous infusion of placebo in addition to oseltamivir
Trial: NCT02355665
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match nicotine spray
Trial: NCT01800162
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.
Trial: NCT02095171
Drug: PRX002
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02611973
Drug: Hydroxyurea treatment (HU)
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HU maintenance
Trial: NCT00939094
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, once daily
Trial: NCT00525512
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral inhalation of once-daily placebo matching tiotropium via handihaler
Trial: NCT03733119
Drug: Akt/ERK Inhibitor ONC201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01863459
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02510976
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01903460
Drug: LUM001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01903460
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no